share_log

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Benzinga ·  Nov 14, 2024 18:20  · Ratings

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment